Core Viewpoint - As of January 21, 2026, Kangtong Medical (301515) reported a closing price of 24.51 yuan, experiencing a slight decline of 0.28% with a turnover rate of 3.8% and a trading volume of 24,900 hands, amounting to a transaction value of 61.21 million yuan [1] Group 1: Financial Performance - For the first three quarters of 2025, Kangtong Medical reported a main revenue of 344 million yuan, a year-on-year decrease of 30.06% [2] - The net profit attributable to shareholders was -10.21 million yuan, reflecting a year-on-year decline of 150.92% [2] - The net profit after deducting non-recurring items was -12.87 million yuan, down 176.82% year-on-year [2] - In Q3 2025, the company achieved a single-quarter main revenue of 79.12 million yuan, which is a year-on-year increase of 42.81% [2] - The single-quarter net profit attributable to shareholders was -1.80 million yuan, a year-on-year decrease of 138.94% [2] - The single-quarter net profit after deducting non-recurring items was -2.60 million yuan, down 182.34% year-on-year [2] - The company's debt ratio stood at 40.94%, with investment income of -0.18 million yuan and financial expenses of 0.54 million yuan, while the gross profit margin was 22.45% [2] Group 2: Capital Flow - On January 21, 2026, the net outflow of main funds was 9.66 million yuan, accounting for 15.77% of the total transaction value [1] - The net outflow of speculative funds was 1.18 million yuan, representing 1.93% of the total transaction value [1] - The net inflow of retail funds was 10.84 million yuan, making up 17.71% of the total transaction value [1]
股票行情快报：港通医疗（301515）1月21日主力资金净卖出965.52万元